^
Association details:
| Biomarker: | H3.3K27M |
|---|---|
| Cancer: | Glioma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeted therapy with anlotinib for a H3K27M mutation diffuse middle glioma patient with PDGFR-a mutation: a case report
Published date:
11/23/2021
Excerpt:
Anlotinib is a multitarget tyrosine kinase inhibitor, which has not been reported for H3K27M-mt DMG treatment. Here, we firstly reported an adult multifocal H3K27M-mt DMG patient benefiting from anlotinib. This report provides a promising treatment option for H3K27M-mt DMG patients.
DOI:
10.1007/s00701-021-05061-1
